SITC 2026 has ended. This guide stays up as the record of who was there. Next: SITC 2027, Nov 3–7, 2027 in National Harbor

AC

The Angeles Clinic and Research Institute at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

The Angeles Clinic and Research Institute brings 3 presentations to SITC 2026 in Phoenix. Its program centres on bispecific drugs that block VEGF and the PD-1 pathway at once, set within a debate over whether the approach lives up to its promise. It also reports early results for brenetafusp, alone or with tebentafusp, in metastatic uveal melanoma.

OrganizationSITC 2026 Attendance
AC
The Angeles Clinic and Research Institute
Los Angeles, CA
Cancer centres & hospitals
Oncology practice and clinical research institute in Los Angeles, affiliated with Cedars-Sinai.
Session
Fri Nov 6
11:45am–12:15pm
Clinical Oral Abstract Session
Clinical
  1. 11:45am–12:00pmVGX-3100 DNA immunotherapy for HPV-16/18–associated cervical high-grade squamous intraepithelial lesions: a phase III randomized trialInovio
  2. 12:00pm–12:15pmIDP-023 allogeneic g-NK cells combined with isatuximab in relapse/refractory multiple myeloma: complete safety, efficacy, and tumor microenvironment remodeling from a Phase 1/2 First-in-Human studyIndapta Therapeutics
Talk
Sun Nov 8
8:10am–8:15am
Session
Sun Nov 8
10:45am–12:25pm
COOPERATIVE BINDING: The bi-specific VEGF/PD(L)-1 Inhibitor Approach to cancer immunotherapy: Savior or Pretender?
New agents
  1. 10:45am–11:00amVascular Normalization by anti-VEGF TreatmentMassachusetts General Hospital
  2. 11:00am–11:15amVascular and Immune Remodeling: Lessons from Clinical VEGF InhibitionFrancis Crick Institute
  3. 11:15am–11:30amClinical Results with VEGFR TKI + IO in RCC and Other DiseasesGeorgetown Lombardi Comprehensive Cancer Center
  4. 11:30am–11:45amBiology and Clinical Results of Anti-VEGF+PD1 BispecficsMD Anderson Cancer Center
  5. 11:45am–12:00pmState of the Union: Current Protocols with VEGF/PD-(L)1The Angeles Clinic and Research Institute
  6. 12:00pm–12:10pmSTK-012, a first-in-class α/β IL-2 receptor biased partial agonist enhances the anti-tumor efficacy of bispecific PD-1/VEGF-targeting antibodiesSynthekine

Explore the full SITC 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Phoenix. Leave your work email and we’ll be in touch.

Privacy

Download the full SITC 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at The Angeles Clinic and Research Institute

Tell us what you sell and we’ll find the people at The Angeles Clinic and Research Institute most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction